GLAXOSMITHKLINE AND AMPLIMMUNE FORM GLOBAL STRATEGIC COLLABORATION
Alliance to Focus on AMP-224 for Cancer and Other Diseases
Rockville, MD, August 4th, 2010 - Amplimmune, Inc. today announced that it has entered into a broad strategic alliance with GlaxoSmithKline (GSK) to further
develop PD-1 targeting therapies that may be effective in the treatment of cancer and other diseases. GSK will obtain exclusive worldwide rights to AMP-224 as
well as other potential next generation fusion proteins that target PD-1.
Under the terms of this agreement, GSK will pay Amplimmune a non-refundable upfront payment of $23 million. Amplimmune is eligible to receive up to $485
million in regulatory, development and sales milestone payments - including milestones associated with IND filing and conducting a Phase 1 trial of AMP-224. Amplimmune
may also receive up to double digit royalties on global sales.
The collaboration will focus primarily on development of AMP-224, Amplimmune's Fc-fusion protein of the B7-DC ligand (also known as PD-L2), which
targets PD-1. ÊIn vivo studies with AMP-224 suggest that this product candidate can induce immune responses to tumors and pathogens sufficient to ameliorate
disease.Ê Under the terms of the agreement, Amplimmune will be responsible for conducting a Phase 1 trial in cancer patients expected to begin in 2011, as well
as completing cGMP manufacturing and GLP toxicology studies that support that first time in human study.Ê Research directed toward understanding the mechanism
of action of AMP-224 and its therapeutic potential in oncology, infectious diseases and vaccine applications will be conducted by Amplimmune and GSK as part of the
collaboration. In addition, the parties may develop next generation protein fusion candidates that target PD-1. GSK will be responsible for all other development
and manufacturing activities and will have worldwide commercialization rights.
"We are very pleased to establish this broad alliance with GSK on our AMP-224 program," said Michael S. Richman, Amplimmune's President and Chief Executive
Officer. Richman continued, "This partnership is an example of pharma and biotech companies working together towards a common goal of developing novel therapies
for patients with unmet medical need and we look forward to advancing AMP-224 into clinical testing".
PD-1 and its ligands play key roles in regulating T-cell mediated immune responses. High levels of PD-1 on T cells can lead to functional impairment of T cells
resulting in ineffective anti-tumor and anti-microbial immunity. Targeting PD-1 on cells with high levels of PD-1 can restore immune function, resulting in
tumor eradication and enhanced protection against infection.
About Amplimmune, Inc.
Founded in 2007 and headquartered in Rockville, MD, Amplimmune is focused on developing novel biologics that are key co-stimulatory/co-inhibitory molecules
that rebalance the immune system and are intended for treating cancer, autoimmune disease, infectious disease, and transplantation. With its strong product-based focus, Amplimmune
is rapidly advancing two lead molecules toward clinical development: AMP-224 in the area of cancer and infectious disease; and AMP-110 for autoimmune diseases. Working
closely with its founders at Johns Hopkins University and other collaborators, Amplimmune is expanding its technology base in the area of immune co-stimulatory/co-inhibitory
molecules and has assembled a large foundation of reagents, models, know-how, and intellectual property to further develop its product pipeline as well as to discover novel
biomarkers, ligands, and receptors. The company is funded by InterWest Partners and The Wellcome Trust. For more information, please visit www.amplimmune.com.
Gary Fanger, Ph.D.